RecruitingNot ApplicableNCT05501080

The Effect of SAAE on Ventricular Remodeling in PA Patients

The Effect of Selective Adrenal Artery Embolization and Spironolactone on Ventricular Remodeling in Nondominant Lateral Secretory Primary Aldosteronism： A Randomized Controlled Clinical Study

Sponsor

Second Affiliated Hospital of Nanchang University

Enrollment

112 participants

Start Date

Sep 1, 2022

Study Type

INTERVENTIONAL

Conditions

Primary Aldosteronism

Summary

The study aims to assess the effect of superselective adrenal arterial embolization on ventricular remodeling in primary aldosteronism without lateralized aldosterone secretion by comparing it with spironolactone therapy.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Spironolactone and Super selective adrenal artery embolization for people with primary aldosteronism. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERSuper selective adrenal artery embolization

Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.

DRUGSpironolactone

Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.

Locations(1)

The Second Affiliated Hospital of Nanchang University

Nanchang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05501080

Related Trials

Study on the Application of Liquid Chromatography-Tandem Mass Spectrometry for the Determination of Aldosterone and Renin Activity in the Diagnosis of Primary Aldosteronism by Captopril Test

NCT076918011 location

Efficacy and Safety of Finerenone Compared to Spironolactone in Treatment of Primary Aldosteronism

NCT076889281 location

Diagnosing Variable Primary Aldosteronism.

NCT057657861 location

Study on the Diagnostic Cut-off Point of 24-hour Urinary Aldosterone Measured by Liquid Chromatography-Tandem Mass Spectrometry in the Diagnosis of Primary Aldosteronism in the Oral Sodium Loading Test

NCT076351341 location

Study on Cutoff Revision Effects and Evaluation of NNT in Primary Aldosteronism

NCT076214581 location